Pulmonary hypertension: pathogenesis and management

Area of Science:

• Cardiovascular Medicine
• Pulmonology
• Molecular Biology

Background:

• Pulmonary hypertension (PH) pathogenesis involves complex interactions of vasodilators, vasoconstrictors, and signaling pathways.
• Cytokines, chemokines, and growth factors play crucial roles in PH development.
• Comprehensive clinical assessment and targeted investigations are essential for PH diagnosis.

Purpose of the Study:

• To review the current understanding of pulmonary hypertension pathogenesis.
• To discuss diagnostic approaches for pulmonary hypertension.
• To outline current and emerging treatment strategies for pulmonary hypertension.

Main Methods:

• Literature review of recent advancements in PH research.
• Analysis of diagnostic criteria and investigation protocols for PH.
• Evaluation of therapeutic interventions for secondary and idiopathic PH.

Main Results:

• Significant progress in understanding PH molecular mechanisms, including intracellular signaling.
• Established diagnostic pathways combining clinical evaluation with targeted investigations.
• Efficacy of established treatments like oxygen and diuretics for right heart failure.
• Emergence of novel therapies for idiopathic pulmonary hypertension, including prostanoids, endothelin receptor antagonists (e.g., bosentan), and PDE-5 inhibitors (e.g., sildenafil).

Conclusions:

• Continued research into PH pathogenesis is vital for developing future therapies.
• Personalized treatment approaches targeting underlying causes and specific pathways are key.
• The therapeutic landscape for PH is rapidly evolving with promising new agents.